-
Abstract Number: 1874
Extensive Modeling-Based Bone Formation After 2 Months of Romosozumab Treatment: Results from the FRAME Clinical Trial
-
Abstract Number: 1875
Subject Characteristics and Changes in Bone Mineral Density After Transitioning from Denosumab to Alendronate in the Denosumab Adherence Preference Satisfaction (DAPS) Study
-
Abstract Number: 1876
Effect of Discontinuation of Denosumab in Subjects with Rheumatoid Arthritis Treated with Glucocorticoids
-
Abstract Number: 1877
Romosozumab Improves Lumbar Spine Bone Mineral Density and Bone Strength Greater Than Alendronate as Assessed by Quantitative Computed Tomography and Finite Element Analysis in the ARCH Trial
-
Abstract Number: 1878
Quantifying the Placebo Effect After Intra-Articular Injections: Implications for Trials and Practice
-
Abstract Number: 1879
The Relation of Pain Sensitization and Conditioned Pain Modulation to Pain Patterns in Knee Osteoarthritis: The Multicenter Osteoarthritis Study
-
Abstract Number: 1880
Baricitinib 4 Mg and 2 Mg Once Daily Reduced Pain in Both Patients Who Were Opioid Users and Non-users in Active Rheumatoid Arthritis: A Post-hoc Analysis of Phase 3 Trials
-
Abstract Number: 1881
Association of Pain Centralization with DMARD Response in Active RA
-
Abstract Number: 1882
Anti-CCP Antibody and Pain Sensitization in Rheumatoid Arthritis
-
Abstract Number: 1883
Elucidating Pain Mechanisms in Polyarticular Juvenile Idiopathic Arthritis Patients
-
Abstract Number: 1884
Autoantibodies to Malondialdehyde-acetaldehyde Preceding the Diagnosis of Rheumatoid Arthritis
-
Abstract Number: 1885
A Search to the Target Tissue in Which RA-specific Inflammation Starts: A Detailed MRI Study to Improve Identification of RA-specific Features in the Phase of Clinically Suspect Arthralgia
-
Abstract Number: 1886
Antibody Systems Targeting Citrullinated, Carbamylated, and Peptidyl Arginine Deaminase Autoantigens Distinguish Rheumatoid Arthritis in Combination with Rheumatoid Factors
-
Abstract Number: 1887
Anti-Mitochondrial Antibodies Predict Severe Erosive Disease in Rheumatoid Arthritis
-
Abstract Number: 1888
Serum Calprotectin Is a Prognostic Marker for Drug-Free Remission in RA
- « Previous Page
- 1
- …
- 126
- 127
- 128
- 129
- 130
- …
- 198
- Next Page »